Abstract
Kinin B1 receptor (B1R) contributes to insulin resistance, an early event in type 2 diabetes, through the upregulation and activation of the inducible form of nitric oxide synthase (iNOS), pro-inflammatory cytokines and the oxidative stress. This study addresses the hypothesis that inhibition of kininase 1 (carboxypeptidase M, CPM), the key enzyme involved in the biosynthesis of B1R agonists, could exert the same beneficial effects to B1R antagonism in insulin resistance. Male Sprague-Dawley rats were made insulin resistant with a drinking solution containing 10% D-glucose for a period of 9 weeks. Control rats received tap water. During the last week, kininase 1 was blocked with Mergetpa (1 mg kg−1 twice daily, s.c.) and the impact was determined on insulin resistance (HOMA index), metabolic hormone levels, oxidative stress and the expression of several markers of inflammation by western blot and qRT-PCR. Glucose-fed rats displayed hyperglycemia, hyperinsulinemia, hyperleptinemia, insulin resistance, hypertension, positive body weight gain, and enhanced expression of B1R, CPM, iNOS, and IL-1β in renal cortex, aorta and liver. Markers of oxidative stress (superoxide anion and nitrotyrosine expression) were also enhanced in aorta and renal cortex. Mergetpa reversed and normalized most of those alterations, but failed to affect leptin levels and hypertension. Pharmacological blockade of kininase 1 (CPM) exerted similar beneficial effects to a 1-week treatment with a B1R antagonist (SSR240612) or an iNOS inhibitor (1,400 W). These data reinforce the detrimental role of B1R in insulin resistance and recommend CPM as a new therapeutic target.
Introduction
Kininase I-type carboxypeptidases are key enzymes involved in the biotransformation of native kinin agonists (bradykinin (BK) and Lys-BK or kallidin) acting at the constitutive B2 receptor (B2R) into B1 receptor agonists (des-Arg9-BK and Lys-des-Arg9-BK) by specifically removing the COOH-terminal Arg residue (Zhang et al., ). An important constitutively active membrane-bound kininase 1 is carboxypeptidase M (CPM, EC 3.4.17.12), an Arg-carboxypeptidase expressed in a wide variety of cell types, including renal, vascular, neural, pulmonary, and immune cells (Deiteren et al., ). This enzyme is strategically localized to regulate kinin activity in inflammatory processes as it is upregulated during tissue damage and by pro-inflammatory cytokines similarly to the B1R (Schremmer-Danninger et al., ; Deiteren et al., ; Kashuba et al., ; Couture et al., ). In addition to generating B1R agonists in close proximity to the receptor, biochemical studies in transfected cells suggest that CPM interacts with the B1R to enhance B1R signaling. Kinin (BK or kallidin) binding to the CPM active site causes a conformational activation of the B1R (Zhang et al., ) and basal binding of CPM to extracellular loop 2 of the B1R results in positive allosteric modulation of B1R signaling to its orthosteric agonist (Zhang et al., ). Recently, CPM and B1R were found upregulated along with the inducible nitric oxide synthase (iNOS) and interleukin-1β (IL-1β) in aorta, renal cortex and liver in a rat model of insulin resistance induced by high glucose feeding (Haddad and Couture, ). Inhibition of iNOS for 1-week with 1,400 W (N- (3-aminomethyl-benzyl acetamidine) (Haddad and Couture, ) or B1R with SSR240612 (Dias et al., ; Dias and Couture, ,) reversed insulin resistance and its associated metabolic features (hyperglycemia, hyperinsulinemia) through the inhibition of the oxidative stress and the nuclear factor NF-κB pathway leading thereby to the concomitant suppression of CPM, B1R, iNOS, and IL-1β overexpression. These studies provided evidence that iNOS and B1R are engaged in a reciprocal upregulation that contributes to insulin resistance and peripheral inflammation.
In addition to upregulating iNOS in insulin resistance, B1R can activate iNOS via Gαi and the Src-dependent activation of the ERK/MAPK pathway leading to a large production of nitric oxide (NO) (Kuhr et al., ; Brovkovych et al., ). Moreover, B1R stimulation was shown to enhance the production of superoxide anion (O2•−) through NADPH oxidase in vessel of glucose-fed rats and in human epithelial cells (Dias et al., ; Talbot et al., ). B1R-induced overproduction of NO and O2•− is harmful because both molecules can interact rapidly to form peroxynitrite (ONOO−), a highly toxic molecule, which causes DNA damage that alters gene expression, inflammation and oxidative stress, notably lipid peroxidation of membranes and nitration of various proteins (enzymes, transporters, ionic pumps, ion channels) (Johansen et al., ; Ascenzi et al., ). We reported that prolonged inhibition of iNOS with 1,400 W (Haddad and Couture, ) blunted the production of peroxynitrite in the model of insulin resistance, suggesting that this oxidative pathway contributes to the upregulation of the biomarkers of inflammation (iNOS, CPM, B1R, and IL-1β) and represents an important mechanism leading to insulin resistance.
The present study was designed to test the hypothesis that inhibition of CPM with Mergetpa also named Plummer's inhibitor (Plummer and Ryan, ; Charest-Morin et al., ) is a valid strategy to prevent the biosynthesis of B1R agonists and thereby may offer the same therapeutic effect to B1R antagonists in insulin resistance. Mergetpa can also prevent the biotransformation of plasma kinins by carboxypeptidase N (CPN), the plasma kininase 1 (Erdos and Sloane, ; Salgado et al., ). However, intriguing reports mentioned that dynorphin A may be an endogenous ligand of BK receptors (Lai et al., , ; Lee et al., ) while cathepsin X localized at the surface of endothelial cells, in macrophages and monocytes can produce B1R ligands from BK and Lys-BK (Nagler et al., ). Thus, the use of Mergetpa should ascertain whether B1R is activated by its classical kinin metabolites des-Arg9-BK and Lys-des-Arg9-BK derived from kininase 1. Therefore, the impact of a 1-week pharmacological treatment with Mergetpa was determined on insulin resistance, metabolic hormones levels, hypertension, vascular and non-vascular inflammatory markers (iNOS, B1R, CPM, IL-1β) and oxidative stress (O2•− and ONOO−) in the model of insulin resistance induced by high glucose feeding. This study tends to support the contribution of kininase I and its active classical B1R metabolites in insulin resistance. Because kininase 1 inhibition reproduces the therapeutic effects of B1R antagonists, CPM may represent a new therapeutic target.
Materials and methods
Animal care and experimental procedures
All experimental methods and animal care procedures were approved by the Animal Care Committee of the Université de Montréal (protocol 11–140) in accordance with the Canadian Council on Animal Care and in compliance with the ARRIVE guidelines (Kilkenny et al., ; McGrath and Lilley, ). Male Sprague-Dawley rats (24–30 days old, 50–75 g) were purchased from Charles River Laboratories (St-Constant, QC, Canada) and housed two per cage, under standard conditions (22.5°C and 42.5% humidity, on a 12 h/12 h light-dark cycle), and allowed free access to a standard chow diet (Charles River Rodent) and to a drinking solution containing 10% D-glucose or tap water (control) for a period of 9 weeks.
On the ninth week, rats fed with glucose (G) or tap water (C) were randomly divided into six groups of six rats: group 1 (G + Mergetpa), group 2 (G + Vehicle), group 3 (C + Mergetpa), group 4 (C + Vehicle), group 5 (G + 1,400 W) and group 6 (C + 1,400 W). Data of groups 5 and 6 were published elsewhere (Haddad and Couture, ). New data are presented herein with Mergetpa (groups 1 and 3), yet the control groups 2 and 4 served in both studies as they were run in the same series of experiments. Mergetpa (DL-2-Mercaptomethyl-3-guanidinoethylthiopropanoic acid), a high affinity and reversible inhibitor of Arg-carboxypeptidase (CPM/CPN named kininase I) (Plummer and Ryan, ; Charest-Morin et al., ) was purchased from Calbiochem (La Jolla, CA, USA). It was given s.c. twice daily at 12 h intervals at the dose of 1 mg.kg−1 in a volume of 1 mL.kg−1 for 7 days. The vehicle (saline) was given in groups 2 and 4. The impact of vehicle (saline) itself was not tested in tap water (C) and glucose (G) groups as key data (Figures 1, 2 and B1R expression) were similar to those obtained earlier in C and G groups not treated with vehicle (Dias et al., ). Thus, the effect of Mergetpa was compared to a placebo (vehicle) in both C and G groups. In a rare study using Mergetpa in vivo, a bolus dose of 10 mg.kg−1 followed by 1 mg.kg−1 per min continuous infusion potentiated the hypotensive response to intraarterial injection of BK (Salgado et al., ). Thus, we selected the minimal dose of 1 mg.kg−1 twice a day. A treatment of 1-week was used to enable better comparison with our earlier studies using 1-week treatment with the iNOS inhibitor 1,400 W and the B1R antagonist SSR240612 (Dias et al., ; Dias and Couture, ,; Haddad and Couture, ). During the last week, groups 1, 2, 3, and 4 were subjected to several measurements, including systolic blood pressure, blood glucose and body weight.
Figure 1
Figure 2
At the end of the ninth week, the blood was collected by cardiac puncture in overnight-fasted rats under isoflurane anesthesia. Blood samples were collected in tubes containing anticoagulant (Heparin; Sandoz, Boucherville, QC, Canada), and the plasma was separated by centrifugation at 600 × g for 15 min at 4°C and stored at −20°C. Tissues and organs (thoracic aorta, kidneys, liver) were removed and kept frozen at −80°C. The renal cortex was dissected out just prior to experiment. They were selected to enable comparison with our previous studies carried out with the iNOS inhibitor 1,400 W and the B1R antagonist SSR240612 (Dias et al., ; Dias and Couture, ; Haddad and Couture, ). Proteins, DNA and RNA of these organs were extracted to measure the expression of several inflammatory biomarkers by western blotting and quantitative RT-PCR (qRT-PCR). Superoxide anion was measured in the aorta using a chemiluminescence technique and lucigenin.
Measurement of systolic blood pressure
Systolic blood pressure was measured by tail-cuff plethysmography using a pad heated at 37°C under the tail. The values were registered with the system Instruments ADI (ADI Instruments Inc., Colorado, CO, USA) assisted by the ADI Instruments software (Pro7.Ink Chart Lab). Each value corresponded to the average of 5–7 measurements taken at 1–2 min intervals. Rats were familiarized with the tail-cuff system once a day for a week before starting the systolic blood pressure measurements.
Plasma analysis
Blood glucose concentration was determined with a glucometer (Accu-Chek Aviva; Roche Diagnostics, Laval, QC, Canada). The plasma insulin and leptin concentrations were determined by RIA (rat insulin RIA kit and rat leptin RIA kit) from Millipore (St. Charles, MO, USA). The homeostasis model assessment (HOMA) index was used to assess insulin resistance by calculating the value of fasting insulin and glucose with the following formula: [insulin (μU·mL−1) × glucose (mmol·L−1)/22.5] (Matthews et al., ).
Measurement of superoxide anion
Superoxide anion (O2•−) was measured in the thoracic aorta with the chemiluminescence method using lucigenin (Munzel et al., ; Haddad and Couture, ). Slices of thoracic aorta (2–5 mg) were pre-incubated in a Krebs-HEPES buffer (saturated with 95% O2 and 5% CO2 at room temperature) for 30 min and transferred to a scintillation vial containing 5 μM of lucigenin to determine the basal level of O2•−. Chemiluminescence was then recorded every minute for 10 min in a dark room using a liquid scintillation counter (Wallac 1409, Turku, Finland). The background was counted using a vial with no tissue solution. The final value was calculated as follows: (tissue value − background value) ÷ tissue dry weight and was expressed in cpm.mg−1 of dry weight tissue.
Western blot analysis
The western blot was performed as previously described (Pouliot et al., ; Haddad and Couture, ). Dynein and β-actin were used as standard proteins. A quantitative analysis of proteins was provided by scanning densitometry using the MCID-M1 system (Imaging Research, St. Catharines, ON, Canada).
Detection of B1R was made with a selective antibody (1:1,000) rose in rabbits (Biotechnology Research Institute, Montreal, QC, Canada) against a conserved amino acid sequence from mouse and rat B1R protein. The epitope used contained 15 amino acids localized in the C-terminal part of the B1R (VFAGRLLKTRVLGTL). Care was taken to avoid sequences with similarity to related mammalian proteins, including the opposite B2R. One negative control was run using the pre-immune serum. Specificity of anti-B1R antibody was further determined using mouse kidney extracts from wild-type and B1R knockout (KO) mice (Lin et al., ; Lacoste et al., ).
The other primary antibodies were as follows: dynein (1:4,000 mouse, SC-13524), β-actin (1:5,000 mouse, SC-47778), IL-1β (1:500 rabbit, SC-7884), iNOS (NOS2) (1:1,000 rabbit, SC-650), carboxypeptidase M (1:500 rabbit, SC 98698) (SC: Santa Cruz Biotechnology, CA, USA), and nitrotyrosine (1:1,500 mouse,1A6-05233; Millipores, Billerica, MA, USA). Secondary antibodies were horseradish peroxidase (HRP)-linked goat anti-rabbit SC-2004 and HRP-linked goat anti-mouse SC-2005 (Santa Cruz) used at dilution of 1:25,000 (for B1), 1:5,000 (for Dynein, β-actin, IL-1β, iNOS, and CPM) and 1:3,000 (nitrotyrosine).
Quantitative real-time polymerase chain reaction (qRT-PCR)
At sacrifice, around 10 mg of tissue (renal cortex, liver and thoracic aorta) were put in a RNAlater stabilization reagent (QIAGEN, Toronto, ON, Canada) and frozen at −56°C. Total RNA was extracted from the tissue using Qiazol according to the manufacturer's instructions. The single-stranded cDNA was synthesized according to the procedure in the manual supplied by Bio-Rad. qRT-PCR was performed in the SYBR Green Master Mix (QIAGEN) by adding 300 nM of each primer and the signal was detected by the Mx3000p device (Stratagene, La Jolla, CA, USA) and using rat 18S as standard. The primer pairs were designed by Vector NTI software as documented earlier (Haddad and Couture, ). The PCR conditions were: 95°C for 15 min followed by 46 cycles at 94°C for 15 s, 60°C for 30 s and 72°C for 30 s. The cycle threshold value represents the number of cycles during which a fluorescent signal increases above the background noise. The relative quantification of gene expression was analyzed by the method of 2−ΔΔCt (Livak and Schmittgen, ).
Statistical data analysis
Data are presented as mean ± SEM, and n represents the number of rats in each group. Statistical analysis was performed using Prism™ version 5.0 (GraphPad Software Inc., La Jolla, CA, USA); data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., ). Statistical significance was determined with Student's t-test for unpaired samples or with the one-way ANOVA followed by the Bonferroni test for multiple comparisons when F achieved P < 0.05 and there was no significant variance in homogeneity. Only the value of P ≤ 0.05 was considered to be statistically significant.
Results
Effect of Mergetpa on clinical parameters
Blood glucose level was significantly increased by two-fold (P < 0.05) in overnight-fasted glucose-fed rats compared with control rats, yet after 1-week treatment with Mergetpa (1 mg kg−1 twice daily) glycemia was reduced to level that was no longer significantly different from control values. Plasma insulin level was significantly increased by four-fold (P < 0.05) in glucose-fed rats and was halved by the treatment with Mergetpa, but this reduction did not reach significance. The HOMA index of insulin resistance was also significantly enhanced (P < 0.05) in glucose-fed rats, yet this value was markedly reduced (P < 0.05) but not completely normalized by Mergetpa. In contrast, the same treatment with Mergetpa failed to affect glycemia, insulinemia and the HOMA index in control rats (Figure 1).
The body weight was not significantly different between glucose-fed rats and control rats before (8 weeks) and after (9 weeks) treatment with Mergetpa (Table 1). However, the gain in body weight was significantly higher (P < 0.05) in glucose-fed rats after 9 weeks when compared with age-matched controls. The 1-week treatment with Mergetpa had no impact on the gain in body weight in control rats, but a significant loss in body weight gain (P < 0.05) was measured after treatment with Mergetpa in glucose-fed rats. The 1-week treatment with Mergetpa had no significant effect on plasma leptin levels in both control and glucose-fed rats, which remained significantly enhanced (P < 0.05) in the latter group as compared with control values. Systolic blood pressure was significantly enhanced (P < 0.05) in 9-week glucose-fed rats compared with control rats and the high systolic blood pressure value was not significantly affected by the 1-week treatment with Mergetpa (Table 1).
Table 1
| Parameters | Control + vehicle | Glucose + vehicle | Control + mergetpa | Glucose + mergetpa |
|---|---|---|---|---|
| Body weight at the initiation of protocol (g) | 114 ± 3 | 110 ± 3 | 107 ± 3 | 111 ± 2 |
| Body weight (g) at 8 weeks | 587 ± 25 | 592 ± 29 | 538 ± 38 | 622 ± 29 |
| Body weight (g) at 9 weeks | 603 ± 26 | 635 ± 18 | 554 ± 38 | 604 ± 17 |
| Body weight gain/loss (g) | 16 ± 2 | 43 ± 2* | 16 ± 4 | (−)18 ± 2.0+# |
| Plasma leptin (ng.ml−1) | 3.8 ± 0.3 | 10.4 ± 2.2* | 4.5 ± 1.4 | 11.7 ± 2.6# |
| Systolic blood pressure (mm Hg) at 9 weeks | 109 ± 3 | 127 ± 3* | 119 ± 4 | 129 ± 6 |
Body weight, plasma leptin levels and systolic blood pressure.
Values represent the mean ± SEM of six rats per group. Statistical comparison (*) to control + vehicle, (+) to glucose + vehicle and (#) to control + Mergetpa is indicated by
P < 0.05,
P < 0.05,
P < 0.05.
Data in vehicle treated rats are from a previous study (Haddad and Couture, ) but performed simultaneously.
Effect of Mergetpa on oxidative stress
The oxidative stress was assessed by the measurement of superoxide anion and the expression of nitrotyrosine, a marker of peroxynitrite (ONOO−). The latter molecule causes tyrosine nitration by the covalent addition of NO2 to tyrosine residues in various proteins thereby affecting protein function and stability. Data depicted in Figure 2 show that the basal production of superoxide anion was significantly increased (P < 0.05) in the aorta of glucose-fed rats when compared with control rats. The 1-week treatment with Mergetpa brought back to control values the enhanced basal production of superoxide anion in the aorta of glucose-fed rats. Mergetpa did not affect significantly the production of superoxide anion in control aorta.
Nitrotyrosine expression was markedly enhanced (P < 0.05) in the renal cortex (Figure 3A) and aorta (Figure 3B) of glucose-fed rats as visualized by increases in the intensity of nitrotyrosine epitopes and the occurrence of new tyrosine nitration proteins between 50 and 250 kDa (renal cortex) or 50 and 150 kDa (aorta) when compared to control tissues. Treatment with Mergetpa significantly reduced (P < 0.05) the intensity of nitrotyrosine-containing proteins in renal cortex and aorta of glucose-fed rats to levels not significantly different from control values. Nitrotyrosine expression was also significantly reduced in control aorta but not in control renal cortex by Mergetpa (Figure 3).
Figure 3
Effect of Mergetpa on B1R and carboxypeptidase M expression
Both B1R protein expression and B1R mRNA levels were significantly enhanced (P < 0.05) in renal cortex (Figures 4A,A'), thoracic aorta (Figures 4B,B') and liver (Figures 4C,C') of glucose-fed rats. The 1-week treatment with Mergetpa brought back to control levels B1R protein and mRNA expression in the three tissues of glucose-fed rats, but failed to affect B1R protein and mRNA expression in the same tissues of control rats (Figure 4).
Figure 4
Likewise to B1R, CPM protein expression was significantly enhanced (P < 0.05) in renal cortex, thoracic aorta and liver of glucose-fed rats (Figures 5A–C). Whereas the 1-week treatment with Mergetpa failed to modify CPM protein expression in control tissues, this treatment blocked completely (P < 0.05) the overexpression of CPM in the three studied tissues of glucose-fed rats (Figure 5).
Figure 5
Effect of Mergetpa on iNOS expression
As iNOS is activated by B1R and contributes to insulin resistance, its expression was measured in parallel to B1R and CPM in the three tissues of glucose-fed rats. Data presented in Figures 6A–C show that the protein expression of iNOS was markedly and significantly enhanced (P < 0.05) in the renal cortex, thoracic aorta and liver of glucose-fed rats. The 1-week treatment with Mergetpa abolished the overexpression of iNOS in the three tissues of glucose-fed rats without affecting its basal expression in control rats (Figure 6).
Figure 6
Effect of Mergetpa on IL-1β expression
Because IL-1β is involved in the induction of B1R (Dias et al., ; Dias and Couture, ; Couture et al., ; Haddad and Couture, ), it was of interest to measure the expression of this pro-inflammatory cytokine in the three studied tissues. Thus, it was found that IL-1β protein expression and IL-1β mRNA levels were significantly enhanced (P < 0.05) in renal cortex (Figures 7A,A'), thoracic aorta (Figures 7B,B') and liver (Figures 7C,C') of glucose-fed rats. The 1-week treatment with Mergetpa blocked completely IL-1β protein and mRNA overexpression in the three tissues of glucose-fed rats. While Mergetpa increased significantly IL-1β protein expression in the renal cortex of control rats, it had no significant impact in the other control tissues (Figure 7).
Figure 7
Discussion
This study reinforces the detrimental role for kinin B1R in insulin resistance because the inhibition of the main enzymes (CPM/CPN) involved in the biosynthesis of the endogenous B1R agonists (des-Arg9-BK and Lys-des-Arg9-BK) improved hyperglycemia, hyperinsulinemia and the HOMA index of insulin resistance. This was associated with the correction of body weight gain and the reversal and normalization of the enhanced expression of several markers of inflammation (B1R, CPM, iNOS, and IL-1β in renal cortex, thoracic aorta and liver) and of the oxidative stress (enhanced production of superoxide anion in aorta and nitrotyrosine expression in aorta and renal cortex). Importantly, results obtained with Mergetpa are closely similar to those reported earlier in this model of insulin resistance after 1-week treatment with the B1R antagonist SSR240612 (Dias et al., ; Dias and Couture, ,) or with the selective inhibitor of iNOS 1,400 W (Haddad and Couture, ). It was then suggested that the activation of B1R leads to the formation of peroxynitrite upon post-translational activation of iNOS and NADPH oxidase. In turn, peroxynitrite exerts a positive feedback loop to enhance the expression of B1R. Blockade of iNOS prevented this vicious cycle and the pro-inflammatory effects of B1R (Haddad and Couture, ). Herein, we suggest that peroxynitrite can also exert a positive feedback loop to enhance the expression of CPM providing further endogenous agonists to activate B1R. This appears a feasible mechanism for B1R upregulation as B1R can be upregulated by its own agonist (Schanstra et al., ; Couture et al., ). Blockade of B1R in vivo with SSR240612 also reversed the upregulation of B1R in peripheral tissues in glucose-fed rats (Dias et al., ; Dias and Couture, ). Thus, pharmacological blockade of B1R with SSR240612 or the inhibition of the generation of B1R endogenous agonists with Mergetpa yielded the same outcome by suppressing B1R agonists-induced upregulation of B1R and subsequently B1R downstream signaling on iNOS, NADPH oxidase and other markers of inflammation.
Impact of Mergetpa on cardiometabolic targets
Our data are consistent with previous studies showing that B1R contributes to insulin resistance and obesity through a mechanism independent of leptin. Indeed, hyperleptinemia found in glucose-fed rats remained unaffected by the prolonged inhibition of B1R with SSR240612 and iNOS with 1,400 W while body weight gain was reversed by both treatments (Dias and Couture, ; Haddad and Couture, ). Moreover, a similar 1-week treatment with SSR240612 in obese Zucker diabetic fatty rats (ZDF), a model of type 2 diabetes, reversed body weight gain without affecting hyperleptinemia (Talbot et al., ).
Mergetpa failed to reduce high blood pressure associated with high glucose feeding that is not in accord with the anti-hypertensive effect of SSR240612 reported in this model (Dias et al., ). This could be explained by the finding that cerebral but not peripheral B1R are involved in the maintenance of high blood pressure as documented in glucose-fed rats, spontaneously hypertensive rats and angiotensin II-induced hypertension using peptide and non-peptide B1R antagonists (Lungu et al., ; De Brito Gariépy et al., ). At this time, there is no information regarding the possibility that Mergetpa can pass the blood-brain barrier to inhibit brain kininase 1. Further studies will be needed to address this issue. Nevertheless, our data highlight a dissociation regarding the mechanisms underlying insulin resistance and hypertension as previously evidenced with the iNOS inhibitor (Haddad and Couture, ), and support the idea that peripheral B1R do not contribute to hypertension as reported in other rat models (De Brito Gariépy et al., ; Couture et al., ).
Impact of Mergetpa on inflammatory markers
The suppression of the enhanced expression of B1R, CPM, iNOS, and IL-1β by Mergetpa was quite clear in the three studied tissues (renal cortex, thoracic aorta and liver) in glucose-fed rats, suggesting that the inflammatory process was not limited to the vasculature. In agreement with the present findings, 1-week blockade of B1R with SSR240612 reversed the overexpression of vascular and non-vascular B1R, iNOS, and IL-1β in glucose-fed rats (Dias et al., ; Dias and Couture, ,).
Chronic activation of B1R is likely to be amplified by the accumulation of des-Arg9-BK and Lys-des-Arg9-BK at the site of inflammation because the half-life of des-Arg9-BK is 4- to 12-fold longer than that of BK (Decarie et al., ). Upregulation of CPM may also account for the increasing endogenous levels of des-Arg9-kinin metabolites and the subsequent upregulation and activation of B1R in the inflammatory process linked to insulin resistance.
CPM is likely more important than CPN in the metabolic regulation of kinin activity since these vasoactive peptides are primarily considered local hormones (autacoids) playing autocrine and paracrine functions (Carretero and Scicli, ). Membrane-bound CPM has been shown to play a critical role in the generation of specific agonists in close proximity to the B1R (Zhang et al., ), which is supported by our in vivo data using Mergetpa. However, one cannot exclude the possibility that Mergetpa blocks B1R signaling independently of the enzymatic generation of B1R agonists by CPM. Recent molecular studies in stably transfected cells have shown that bradykinin or kallidin binds to CPM (without generating agonist) to induce a conformational change in the enzyme that is transmitted to the B1R causing its activation. Mergetpa blocks this conformational crosstalk by preventing the binding of kinins to CPM (Zhang et al., ). Importantly, the present study confirms the contribution of CPM and excludes the possibility that cathepsin X could intervene in the formation of B1R ligands (Nagler et al., ) or that dynorphin could be an endogenous activator of the B1R (Lai et al., , ; Lee et al., ) in this pro-inflammatory model of insulin resistance.
Limitations of the study
CPM is a largely distributed enzyme that cleaves C-terminal lysine or arginine from other peptides and proteins, including anaphylatoxins, chemokines, enkephalins and growth factors (Deiteren et al., ) that may question its specificity as a pharmacological target. While the regulatory role of CPM in kinins and B1R activity has been fairly well documented (Erdos and Sloane, ; Zhang et al., ,; Couture et al., ; Regoli and Gobeil, ), the impact of CPM on the physiological functions of other endogenous substrates, and particularly in insulin resistance, is still unknown and remains to be studied. In the present study, the inhibition of B1R-agonists formation by Mergetpa has not been directly demonstrated and is not an easy task in vivo due to the short life of these peptides, but the impact of CPM blockade is in accordance with the beneficial effects of B1R antagonism in insulin resistance and its associated oxidative stress and inflammatory mechanisms (Dias et al., ; Dias and Couture, ; Haddad and Couture, ). Mergetpa had no or little significant effect in control rats, which is consistent with the virtual absence of B1R in control rats (Couture et al., ). Hence, findings suggest specificity of action of the drug on CPM and on kinins as the main substrates.
Conclusion
Pharmacological blockade of kininase 1 (CPM) for 1-week provided similar beneficial effects to a corresponding treatment with a B1R antagonist in insulin resistance and peripheral inflammation induced by high glucose feeding. These findings have clinical relevance in the treatment of type 2 diabetes and its complications. Hence, inhibiting kininase I to lower B1R agonists generation may provide a novel therapeutic approach as alternative to B1R antagonists, and has the advantage to enhance the cardioprotective and anti-diabetic effects of the B2R (Regoli and Gobeil, ) by preventing the cleavage of the COOH-terminal-Arg residue on BK and kallidin. The development of a new generation of kininase 1 inhibitors for pharmacotherapy is appealing and would be an asset.
Statements
Author contributions
YH performed the experiments, analyzed the data, made the figures and drafted the manuscript. YH, RC interpreted the data and revised critically the intellectual content. RC designed the study, supervised the work and wrote the final version of the manuscript. All authors agree to be accountable for the content of the work.
Funding
This work was supported by a Grant-in-aids from the Canadian Institutes of Health Research (MOP-119329). YH received a 1-year PhD Studentship award from the Graduate Program in Molecular, Cellular and Integrative Physiology of the Université de Montréal.
Acknowledgments
The authors greatly appreciate the technical assistance of Jacques Sénécal for the treatment with Mergetpa and RIA studies.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer LB and handling Editor declared their shared affiliation, and the handling Editor states that the process met the standards of a fair and objective review.
- BK
bradykinin
- B1R
bradykinin type 1 receptor
- B2R
bradykinin type 2 receptor
- CPM
carboxypeptidase M (membrane)
- CPN
carboxypeptidase N (plasmatic)
- GPCR
G-protein-coupled receptor
- HOMA
homeostasis model assessment index
- IL-1β
interleukin-1β
- Mergetpa
DL-2-Mercaptomethyl-3-guanidinoethylthiopropanoic acid
- NADPH
nicotinamide adenine dinucleotide phosphate
- NO
nitric oxide
- NOS
nitric oxide synthase
- iNOS
inducible nitric oxide synthase
- ONOO−
peroxynitrite
- qRT-PCR
quantitative real-time polymerase chain reaction
- O2•−
superoxide anion.
Abbreviations
References
1
AscenziP.di MasiA.ScioratiC.ClementiE. (2010). Peroxynitrite-an ugly biofactor?BioFactors36, 264–273. 10.1002/biof.103
2
BrovkovychV.ZhangY.BrovkovychS.MinshallR. D.SkidgelR. A (2011). A novel pathway for receptor-mediated post-translational activation of inducible nitric oxide synthase. J. Cell. Mol. Med.15, 258–269. 10.1111/j.1582-4934.2009.00992.x
3
CarreteroO. A.ScicliA. G. (1991). Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension. Hypertension18(3 Suppl.), I58–69. 10.1161/01.HYP.18.3_Suppl.I58
4
Charest-MorinX.RoyC.FortinE. J.BouthillierJ.MarceauF. (2014). Pharmacological evidence of bradykinin regeneration from extended sequences that behave as peptidase-activated B2 receptor agonists. Front. Pharmacol.5:32. 10.3389/fphar.2014.00032
5
CoutureR.BlaesN.GirolamiJ. P. (2014). Kinin receptors in vascular biology and pathology. Curr. Vasc. pharmacol.12, 223–248. 10.2174/1570161112666140226121627
6
CurtisM. J.BondR. A.SpinaD.AhluwaliaA.AlexanderS. P.GiembyczM. A.et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br. J. Pharmacol.172, 3461–3471. 10.1111/bph.12856
7
De Brito GariépyH.CarayonP.FerrariB.CoutureR. (2010). Contribution of the central dopaminergic system in the anti-hypertensive effect of kinin B1 receptor antagonists in two rat models of hypertension. Neuropeptides44, 191–198. 10.1016/j.npep.2009.12.011
8
DecarieA.RaymondP.GervaisN.CoutureR.AdamA. (1996). Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am. J. physiol.271(4 Pt 2), H1340–H1347.
9
DeiterenK.HendriksD.ScharpeS.LambeirA. M (2009). Carboxypeptidase M: multiple alliances and unknown partners. Clin. Chim. Acta. Int. J. clin. Chem.399, 24–39. 10.1016/j.cca.2008.10.003
10
DiasJ. P.CoutureR. (2012a). Suppression of vascular inflammation by Kinin B1 receptor antagonism in a rat model of insulin resistance. J. Cardiovasc. Pharmacol.60, 61–69. 10.1097/FJC.0b013e3182576277
11
DiasJ. P.CoutureR. (2012b). Blockade of kinin B1 receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance. Diabetes Obes. Metab.14, 244–253. 10.1111/j.1463-1326.2011.01521.x
12
DiasJ. P.TalbotS.SenecalJ.CarayonP.CoutureR. (2010). Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS ONE5:e12622. 10.1371/journal.pone.0012622
13
ErdosE. G.SloaneE. M (1962). An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol.11, 585–592. 10.1016/0006-2952(62)90119-3
14
HaddadY.CoutureR. (2016). Interplay between the kinin B1 receptor and inducible nitric oxide synthase in insulin resistance. Br. J. pharmacol.173, 1988–2000. 10.1111/bph.13491
15
JohansenJ. S.HarrisA. K.RychlyD. J.ErgulA. (2005). Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc. Diabetol.4:5. 10.1186/1475-2840-4-5
16
KashubaE.BaileyJ.AllsupD.CawkwellL. (2013). The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers18, 279–296. 10.3109/1354750X.2013.787544
17
KilkennyC.BrowneW. J.CuthillI. C.EmersonM.AltmanD. G (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J. Pharmacol. Pharmacother.1, 94–99. 10.4103/0976-500X.72351
18
KuhrF.LowryJ.ZhangY.BrovkovychV.SkidgelR. A (2010). Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides44, 145–154. 10.1016/j.npep.2009.12.004
19
LacosteB.TongX. K.LahjoujiK.CoutureR.HamelE. (2013). Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice. J. Neuroinflammation10:57. 10.1186/1742-2094-10-57
20
LaiJ.LuoM. C.ChenQ.MaS.GardellL. R.OssipovM. H.et al. (2006). Dynorphin a activates bradykinin receptors to maintain neuropathic pain. Nat. Neurosci.9, 1534–1540. 10.1038/nn1804
21
LaiJ.LuoM. C.ChenQ.PorrecaF. (2008). Pronociceptive actions of dynorphin via bradykinin receptors. Neurosci. Lett.437, 175–179. 10.1016/j.neulet.2008.03.088
22
LeeY. S.MuthuD.HallS. M.Ramos-ColonC.RankinD.HuJ.et al. (2014). Discovery of amphipathic dynorphin a analogues to inhibit the neuroexcitatory effects of dynorphin a through bradykinin receptors in the spinal cord. J. Am. Chem. Soc.136, 6608–6616. 10.1021/ja501677q
23
LinJ. C.TalbotS.LahjoujiK.RoyJ. P.SenecalJ.CoutureR.et al. (2010). Mechanism of cigarette smoke-induced kinin B(1) receptor expression in rat airways. Peptides31, 1940–1945. 10.1016/j.peptides.2010.07.008
24
LivakK.SchmittgenT. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) method. Methods25, 402–408. 10.1006/meth.2001.1262
25
LunguC.DiasJ. P.FrancaC. E.OngaliB.RegoliD.MoldovanF.et al. (2007). Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistanceNeuropeptides41, 375–387. 10.1016/j.npep.2007.09.005
26
MatthewsD. R.HoskerJ. P.RudenskiA. S.NaylorB. A.TreacherD. F.TurnerR. C (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia28, 412–419. 10.1007/BF00280883
27
McGrathJ. C.LilleyE. (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br. J. Pharmacol.172, 3189–3193. 10.1111/bph.12955
28
MunzelT.SayeghH.FreemanB. A.TarpeyM. M.HarrisonD. G (1995). Evidence for enhanced vascular superoxide anion production in nitrate tolerance. a novel mechanism underlying tolerance and cross-tolerance. J. Clin. Invest.95, 187–94. 10.1172/JCI117637
29
NaglerD. K.KrausS.FeierlerJ.MenteleR.LottspeichF.JochumM.et al. (2010). A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists. Int. Immunopharmacol.10, 134–139. 10.1016/j.intimp.2009.09.018
30
PlummerT. H.Jr.RyanT. J (1981). A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. Biochem. Biophys. Res. commun.98, 448–454. 10.1016/0006-291X(81)90860-3
31
PouliotM.HetuS.LahjoujiK.CoutureR.VaucherE. (2011). Modulation of retinal blood flow by kinin B(1) receptor in Streptozotocin-diabetic rats. Exp. Eye Res.92, 482–489. 10.1016/j.exer.2011.03.007
32
RegoliD.GobeilF.Jr. (2015). Critical insights into the beneficial and protective actions of the kallikrein-kinin system. Vasc. Pharmacol.64, 1–10. 10.1016/j.vph.2014.12.003
33
SalgadoH. C.CarreteroO. A.ScicliA. G.MurrayR. D (1986). Effect of DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid on the blood pressure response to vasoactive substances. J. Pharmacol. Exp. Ther.237, 204–208.
34
SchanstraJ. P.BatailleE.Marin CastanoM. E.BarascudY.HirtzC.PesqueroJ. B.et al. (1998). The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J. Clin. Invest.101, 2080–2091. 10.1172/JCI1359
35
Schremmer-DanningerE.OffnerA.SiebeckM.RoscherA. A (1998). B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem. Biophys. Res. commun.243, 246–252. 10.1006/bbrc.1997.7999
36
TalbotS.DiasJ. P.El MidaouiA.CoutureR. (2016). Beneficial effects of kinin B1 receptor antagonism on plasma fatty acid alterations and obesity in Zucker diabetic fatty rats. Can. J. Physiol. Pharmacol.94, 752–757. 10.1139/cjpp-2016-0063
37
TalbotS.LinJ. C.LahjoujiK.RoyJ. P.SenecalJ.MorinA.et al. (2011). Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells. Peptides32, 1447–1456. 10.1016/j.peptides.2011.05.005
38
ZhangX.TanF.BrovkovychV.ZhangY.LowryJ. L.SkidgelR. A (2013a). Carboxypeptidase M augments kinin B1 receptor signaling by conformational crosstalk and enhances endothelial nitric oxide output. Biol. Chem.394, 335–345. 10.1515/hsz-2012-0290
39
ZhangX.TanF.SkidgelR. A. (2013b). Carboxypeptidase M is a positive allosteric modulator of the kinin B1 receptor. J. Biol. Chem.288, 33226–33240. 10.1074/jbc.M113.520791
Summary
Keywords
bradykinin, carboxypeptidase M, inducible nitric oxide, inflammatory markers, insulin resistance, Mergetpa, oxidative stress
Citation
Haddad Y and Couture R (2017) Kininase 1 As a Preclinical Therapeutic Target for Kinin B1 Receptor in Insulin Resistance. Front. Pharmacol. 8:509. doi: 10.3389/fphar.2017.00509
Received
08 June 2017
Accepted
19 July 2017
Published
02 August 2017
Volume
8 - 2017
Edited by
Patrizia Ballerini, Università degli Studi “G. d'Annunzio” Chieti - Pescara, Italy
Reviewed by
Vishal Diwan, Mater Research, Australia; Martina Montagnana, University of Verona, Italy; Luigi Brunetti, Università degli Studi “G. d'Annunzio” Chieti - Pescara, Italy
Updates
Copyright
© 2017 Haddad and Couture.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Réjean Couture rejean.couture@umontreal.ca
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.